Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 2/20 | 0.44 |
| ▸ | CTSS | P25774 | 1/20 | 0.44 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | NOS3 | P29474 | 3/20 | 0.33 |
| ▸ | NOS1 | P29475 | 3/20 | 0.33 |
| ▸ | NOS2 | P35228 | 3/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CFD | P00746 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3570317 | 1.00 | CTSK (0.44) | CTSKCTSSPSENENLMNATSHR | |
| SCHEMBL3567097 | 0.84 | CTSK (0.38) | CTSKCTSSTSHRTGFBR1CA2 | |
| SCHEMBL2563040 | 0.84 | HTT (0.46) | TGFBR1ALDH1A1HTTNOS3NOS1 | |
| SCHEMBL3567095 | 0.84 | CTSK (0.38) | CTSKCTSSTSHRTGFBR1CA2 | |
| SCHEMBL2563038 | 0.84 | HTT (0.46) | TGFBR1ALDH1A1HTTNOS3NOS1 | |
| SCHEMBL27726832 | 0.84 | HTT (0.46) | TGFBR1ALDH1A1HTTNOS3NOS1 | |
| SCHEMBL15312479 | 0.80 | CTSK (0.47) | CTSKCTSSPSENENALDH1A1HTT | |
| SCHEMBL21368000 | 0.79 | CTSS (0.44) | CTSKCTSSPSENENTSHRALDH1A1 | |
| Hydrochloric Acid SCHEMBL15312478 | 0.78 | CTSK (0.46) | CTSKCTSSPSENENALDH1A1HTT | |
| Hydrochloric Acid SCHEMBL15312476 | 0.78 | CTSK (0.46) | CTSKCTSSPSENENALDH1A1HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709644-B2 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2010-05-04 | — | — | US | disclosed |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2007-09-13 | — | — | US | disclosed |
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | LANXESS DEUTSCHLAND GMBH (DE) | 2004-03-04 | — | — | US | disclosed |
| US-5274167-A | A N-(meth)acryloyl amino acid amide | BAYER AKTIENGESELLSCHAFT (DE) | 1993-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044205-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, DECR1, SPIN2B | CTSK 4035/4885CTSS 4045/4885PSENEN 2669/4885 |
| US-20070213536-A1 | Process for the enantiomeric enrichment of cis-8-benzyl-7,9-dioxo-2,8-diazabicyclo[4.3.0]nonane | CYP1B1, CYP8B1, CCR8 | CTSK 4237/4885CTSS 3886/4885PSENEN 2421/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.